Literature DB >> 10462282

Rapid and accurate assessment of glomerular filtration rate in patients with renal transplants using serum cystatin C.

L Risch1, A Blumberg, A Huber.   

Abstract

BACKGROUND: Assessment of renal function in patients with renal transplants is of great importance. Various studies have reported cystatin C as an easily and rapidly assessable marker that can be used for accurate information on renal function impairment. To date, no study is available to define the role of cystatin C in patients with renal transplants.
METHODS: Thirty steady-state patients (50% male/50% female) with status post-kidney transplantation were studied. To assess renal function, cystatin C, creatinine clearance, serum creatinine, beta2-microglobulin (beta2M), and [125I]iothalamate clearance were determined. Correlations and non-parametric ROC curves for accuracy, using a cut-off glomerular filtration rate (GFR) of 60 ml/min, were obtained for the different markers allowing for calculations of positive predictive values (PPV), positive likelihood ratios (PLR), specificity and sensitivity, respectively. Further, to evaluate the usefulness of these markers for monitoring, intraindividual coefficients of variation (CVs) for cystatin C and creatinine measurements were compared in 85 renal transplant patients. Measurements consisted of at least six pairs of results, which were obtained at different time points during routine follow-up.
RESULTS: Cystatin C correlated best with GFR (r=0.83), whereas serum creatinine (r=0.67), creatinine clearance (r=0.57) and beta2M (r=0.58) all had lower correlation coefficients. The diagnostic accuracy of cystatin C was significantly better than serum creatinine (P=0.025), but did not differ significantly from creatinine clearance (P=0.76) and beta2M (P=0.43). At a cut-off of 1.64 mg/l, cystatin C has a PPV of 93%, PLR of 6.4, specificity 89% and sensitivity 70%, respectively. For beta2M, PPV 83%, PLR 1.7, specificity 67% and sensitivity 75% was seen at a cut-off of 3.57 mg/l. Accordingly, at a cut-off of 125 micromol/l for serum creatinine, a PPV 76%, PLR 1.4, specificity 44% and sensitivity 80% was revealed. Finally, at a cut-off of 66 ml/min/1.73 m2 for creatinine clearance, the following characteristics were found: PPV 94%, PLR 7.7, specificity 89% and sensitivity 85%. The intraindividual variation of creatinine was significantly lower than that of cystatin C (P<0.001). With increasing concentrations, their ratios of CV tended towards a value of 1, demonstrating identical variability at low GFR.
CONCLUSION: Together, our data show that in patients with renal transplants, cystatin C, in terms of PPV and PLR, has a similar diagnostic value as creatinine clearance. However, it is superior to serum determinations of creatinine and beta2M. The intraindividual variation of cystatin C is greater than that of creatinine. This might be due to the better ability of cystatin C to reflect temporary changes especially in mildly impaired GFR, most critical for early detection of rejection and other function impairment. Thus, cystatin C allows for rapid and accurate assessment of renal function (GFR) in renal transplants and is clearly superior to the commonly used serum creatinine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462282     DOI: 10.1093/ndt/14.8.1991

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  21 in total

Review 1.  A meta-analysis on diagnostic value of serum cystatin C and creatinine for the evaluation of glomerular filtration function in renal transplant patients.

Authors:  Pan Pan; Hu Binjie; Li Min; Fan Lipei; Ni Yanli; Zhou Junwen; Shi Xianghua
Journal:  Afr Health Sci       Date:  2014-12       Impact factor: 0.927

Review 2.  Measuring glomerular filtration rate in children; can cystatin C replace established methods? A review.

Authors:  Trine Borup Andersen; Anni Eskild-Jensen; Jørgen Frøkiaer; Jens Brøchner-Mortensen
Journal:  Pediatr Nephrol       Date:  2008-10-07       Impact factor: 3.714

3.  A comparison of cystatin C concentrations between patients with chronic interstitial nephritis and glomerular diseases.

Authors:  Nicolas Roberto Robles; Candido Mena; Edgar Chavez; Miguel Angel Bayo; Boris Gonzalez Candia; Antonio Cidoncha; Juan Lopez Gomez; Juan Jose Cubero
Journal:  J Clin Lab Anal       Date:  2017-02-10       Impact factor: 2.352

4.  Cystatin C and serum creatinine as predictors of kidney graft outcome.

Authors:  Visnja Lezaic; Marijana Dajak; Dragana Radivojevic; Stojanka Ristic; Jelena Marinkovic
Journal:  Int Urol Nephrol       Date:  2013-12-14       Impact factor: 2.370

5.  Comparing cystatin C and creatinine in the diagnosis of pediatric acute renal allograft dysfunction.

Authors:  Pauline R Slort; Nergiz Ozden; Lars Pape; Gisela Offner; Wilma F Tromp; Abraham J Wilhelm; Arend Bokenkamp
Journal:  Pediatr Nephrol       Date:  2011-12-30       Impact factor: 3.714

6.  Serum Cystatin C can detect impaired graft function early after renal transplantation.

Authors:  Shi-Ming Zhou; Wei Zhao; Tao Lin; Sheng-Tian Zhao; Hong-Wei Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

7.  Evaluation of serum cystatin-C in dogs with visceral leishmaniasis.

Authors:  S Pasa; G Bayramli; A Atasoy; A Karul; S Ertug; S Ozensoy Toz
Journal:  Vet Res Commun       Date:  2009-01-13       Impact factor: 2.459

8.  Cystatin C--a paradigm of evidence based laboratory medicine.

Authors:  Janice S C Chew; Mohammed Saleem; Christopher M Florkowski; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05

9.  Cystatin C and serum creatinine in estimating acute kidney injury of shock patients.

Authors:  Qiang Li; Jie-Yu Fang; Wei-Ping Wang; Jiang-Hui Liu; Ke-Ke Wang
Journal:  World J Emerg Med       Date:  2010

10.  Early detection of acute kidney injury by serum cystatin C in critically ill children.

Authors:  Neamatollah Ataei; Behnaz Bazargani; Sonbol Ameli; Abbas Madani; Faezeh Javadilarijani; Mastaneh Moghtaderi; Arash Abbasi; Sedigheh Shams; Fatemeh Ataei
Journal:  Pediatr Nephrol       Date:  2013-08-30       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.